🇺🇸 FDA
Pipeline program

JIN-A02

JIN-A02

Phase 2 small_molecule active

Quick answer

JIN-A02 for EGFR Mutant Advanced Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at INTENSITY THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
INTENSITY THERAPEUTICS, INC.
Indication
EGFR Mutant Advanced Non-small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials